Nir Barzilai and Andrea Maier are among the 12 longevity leaders featured recently in a Time Magazine Collection. Both will also be speakers at the upcoming Precision Medicine World Conference 2027 (January 27-29) (PMWC2027) in the meeting’s Precision Aging, Prevention, and Healthspan session, which Barzilai will chair. Maier and Barzilai will be joined by Michael Snyder, Alexander Fleming, Daniel Drucker, Lee Hood, and 20 other prominent longevity speakers in this day-long session. Drucker and Fleming will receive Pioneer Awards, while Maier will receive a Luminary Award to open the session. The PMWC Pioneer Awards are given to venerable individuals whose foresight and ground-breaking contributions to precision medicine propelled the movement in earlier years, allowing it to gain momentum to evolve into the standard of care that it is becoming today. The PMWC Luminary Awards recognize the recent contributions of prominent figures who have accelerated precision medicine into the clinic. In addition to Barzilai and Maier, the Time list of longevity leaders includes Shinya Yamanaka (Nobel Laureate), Gabriel Lyon, David Sinclai, Tony Wyss-Coray, Jamie Justice, Juan Carlos Izpizua Belmonte, Robert Waldinger, Francesca Duncan, Uri Alon, and Myechia Minter-Jordan. You may register for the outstanding PMWC 2027 conference here; and view the current conference program here.
Nir Barzilai, MD, is a preeminent leader in geroscience, demonstrating in his studies that aging has its own biology that drives age-related diseases, a process that can be targeted. At Albert Einstein College of Medicine, he is a professor in the departments of Medicine and Genetics, the director of the Institute for Aging Research, and the director of the Einstein-National Institutes of Health (NIH) Nathan Shock Center of Excellence in the Basic Biology of Aging, and the author of more than 350 papers. He has made seminal discoveries in extending the health and lifespan of animals and discovering pathways for exceptional longevity in humans. He is leading an international effort to approve drugs targeting aging. Targeting Aging with Metformin (TAME) is a specific study conceived by Barzilai to prove that a single drug can combat multiple diseases associated with aging and get FDA approval for targeting aging. Barzilai is a co-founder and the President of the Academy for Health and Lifespan Research (AHLS). He is also on the board of directors of the American Federation for Aging Research, where he co-leads its biomarker effort (FAST), TAME, and Super Agers initiative. He is an Executive of the Longevity Biotech Association (LBA) and serves on the Healthy Longevity Medicine Society council. He authored “Age Later: Health Span, Life Span, and the New Science of Longevity.” Barzilai received a PMWC Luminary Award in 2026.
Andrea Maier, MD, is the director of the NUS Academy for Healthy Longevity, National University of Singapore, and she will receive a PMWC Luminary Award for advancing geroscience from aging biology to healthy longevity medicine. She isa leading figure in geroscience and healthy longevity medicine, termed precision geromedicine. Her work focuses on translating the biology of aging into clinical practice to extend healthspan rather than prolong lifespan. She has led international cohort and intervention studies to understand aging mechanisms and apply them to prevention and care. Maier has shaped precision geromedicine as an organized field. She is the Founding President of the Healthy Longevity Medicine Society, Scientific Advisory Board member of the Biomarkers of Aging Consortium, and serves on the Board of the Academy for Health and Lifespan Research, placing her at the center of defining standards and direction for this emerging area. She also builds the clinical infrastructure needed to move precision geromedicine to implementation, leading the Centre for Healthy Longevity at NUS and founding the NUS Academy for Healthy Longevity, making her a prominent voice connecting ageing biology and clinical medicine.